10-KPeriod: FY2009

DEXCOM INC Annual Report, Year Ended Dec 31, 2009

Filed March 9, 2010For Securities:DXCM

Summary

DexCom, Inc. (DXCM) in its 2010 10-K filing highlights its position as an emerging medical device company focused on continuous glucose monitoring (CGM) systems. The company has launched its third-generation product, the SEVEN PLUS, designed for up to seven days of use, and is also developing in-hospital monitoring solutions in partnership with Edwards Lifesciences. Despite product advancements and growing market potential due to increasing diabetes prevalence, DexCom faces significant risks. Key challenges include achieving broad market acceptance for its products, which are adjunctive to traditional blood glucose monitoring and may not be fully reimbursed by payors. The company has a limited operating history and has incurred substantial losses since inception, with expectations of continued losses in the foreseeable future. Furthermore, DexCom is embroiled in a significant patent infringement lawsuit with Abbott Diabetes Care, which poses a substantial financial and operational risk. Manufacturing capacity, supply chain reliance on single-source suppliers, and regulatory hurdles are also critical areas of concern for investors.

Financial Highlights

25 data points
Beta

Revenue

$29.69M

12.3% Gross Margin

Net Income

-$53.52M

-180.3% Net Margin

EPS (Diluted)

$-0.30

Cash & Equivalents

$3.60M

Free Cash Flow

-$42.38M

Financial Statements
Beta
Revenue$29.69M
Cost of Revenue$26.03M
Gross Profit$3.66M
R&D Expenses$14.29M
SG&A Expenses$35.20M
Operating Expenses$49.49M
Operating Income-$45.83M
Interest Expense$8.04M
Net Income-$53.52M
EPS (Basic)$-0.30

Key Highlights

  • 1DexCom has commercialized its third-generation continuous glucose monitoring system, the SEVEN PLUS, with enhanced accuracy and customization features.
  • 2The company is expanding into the in-hospital glucose monitoring market through a collaboration with Edwards Lifesciences, having received CE Mark approval for an in-hospital system.
  • 3Significant revenue growth is being driven by product sales and development grant revenue from strategic partnerships with Animas and Edwards.
  • 4The company faces substantial financial risks due to a history of net losses and an accumulated deficit, with ongoing expectations of continued losses.
  • 5A major patent infringement lawsuit filed by Abbott Diabetes Care poses a significant threat to DexCom's business and product commercialization.
  • 6Reimbursement from third-party payors remains a critical factor for market adoption, as current coverage is not broad and administrative challenges exist.
  • 7DexCom relies on single-source suppliers for key components, creating vulnerability to supply chain disruptions and price fluctuations.

Frequently Asked Questions

DexCom's primary product is the SEVEN PLUS, a continuous glucose monitoring (CGM) system designed for ambulatory use by people with diabetes. The company is also developing an in-hospital CGM system in partnership with Edwards Lifesciences. As of the filing date, DexCom held an estimated 37% market share in the US CGM market.

DexCom has incurred net losses since its inception and expects to continue doing so in the foreseeable future, with a significant accumulated deficit. The company relies on equity and debt financing to fund its operations, and while it recently completed a follow-on public offering, it anticipates needing additional funds for commercialization and R&D activities. Product reimbursement challenges from third-party payors also impact revenue generation.

DexCom is defending itself against a patent infringement lawsuit filed by Abbott Diabetes Care, Inc. This lawsuit involves multiple patents and reexamination proceedings, posing a significant risk of substantial legal costs, potential injunctions, and material adverse effects on DexCom's business and operations, regardless of the outcome.

DexCom has limited manufacturing capabilities and personnel, and faces risks related to scaling production and maintaining quality. The company relies on several single-source suppliers for critical components, which exposes it to potential supply problems and price fluctuations. DexCom is working to expand manufacturing capacity and improve processes.